Eylea

all catalysts(0)

nothing on the calendar yet

News(10)

• EyePoint’s bid to compete with Eylea falls flat
  EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…
  endpoints · 8h ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 9h ago
• EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
  EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
  biospace · 9h ago
• Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
  Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
  biospace · 6d ago
• Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
  Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
  fiercebiotech · 7d ago
• Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
  Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
  biospace · 18d ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 21d ago
• Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
  Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
  fiercebiotech · 25d ago
• ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
  The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
  biopharma_dive · 1mo ago
• Regeneron immunotherapy combo comes up short in melanoma trial
  A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
  biopharma_dive · 3mo ago